American Journal of Transplantation最新文献_第2页

Finding actionable information in the universe of data 在数据宇宙中寻找可操作的信息。

IF 8.9 2区医学

American Journal of Transplantation Pub Date : 2025-04-01 DOI: 10.1016/j.ajt.2025.01.004

Jennifer Gagnon , Lisa M. McElroy

引用次数: 0

Moving towards outpatient kidney transplantation: a case report.

IF 8.9 2区医学

American Journal of Transplantation Pub Date : 2025-04-01 DOI: 10.1016/j.ajt.2025.03.028

Vicente Garcia-Tomas, Vinayak Rohan, Akansha Agrawal, Tiffany G Liu, Rishi Arora, Alexandria Tran, Matthew Harris, Satish N Nadig

引用次数: 0

Trends in candidate hepatitis C virus nucleic acid amplification test (NAT)+ listing and associated impacts on liver transplantation waitlist outcomes 候选 HCV NAT+ 名单的趋势以及对肝移植候选结果的相关影响。

IF 8.9 2区医学

American Journal of Transplantation Pub Date : 2025-04-01 DOI: 10.1016/j.ajt.2024.10.016

Natalia Salinas Parra , Maarouf A. Hoteit , Puru Rattan , Peter Abt , Nadim Mahmud

{"title":"Trends in candidate hepatitis C virus nucleic acid amplification test (NAT)+ listing and associated impacts on liver transplantation waitlist outcomes","authors":"Natalia Salinas Parra , Maarouf A. Hoteit , Puru Rattan , Peter Abt , Nadim Mahmud","doi":"10.1016/j.ajt.2024.10.016","DOIUrl":"10.1016/j.ajt.2024.10.016","url":null,"abstract":"<div><div>Direct-acting antiviral agents have facilitated the utilization of hepatitis C virus (HCV)+ organs in HCV nucleic acid amplification test (NAT)– recipients. We evaluated trends in HCV NAT+ listing and its impact on transplant probability, waitlist mortality, and likelihood of receiving HCV NAT+ organs using the United Network for Organ Sharing data set of adult patients waitlisted for liver transplantation from January 2016 to September 2023. Multivariable regression models accounting for competing risks were fit to study waitlist outcomes. Initially, 21 776 patients were listed for HCV NAT+ organs whereas 45 378 were not. The percentage of waitlisted patients listed for these organs increased significantly from 2016 to 2023 (8.8% to 60.8%, <em>P</em> < .001). Initial HCV NAT+ listing was associated with a waitlist mortality benefit in 2021-2023 (subhazard ratio 0.73, 95% CI 0.68-0.79, <em>P</em> < .001) and 17% reduced hazard of overall mortality (hazard ratio 0.83, 95% CI 0.78-0.89, <em>P</em> < .001). Sixteen percent of the total protective effect associated with HCV NAT+ listing on overall survival was mediated through actual receipt of HCV NAT+ organs (total excess relative risk of –0.160 and a pure indirect effect of –0.026; <em>P</em> < .001). Patients not listed for HCV NAT+ organs in the modern era are relatively disadvantaged in terms of waitlist outcomes. Although listings have risen over time, there remains center-level and geographic variation.</div></div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 4","pages":"Pages 793-803"},"PeriodicalIF":8.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142491464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The ability of an electronic nose to distinguish between complications in lung transplant recipients 电子鼻区分肺移植受者并发症的能力

IF 8.9 2区医学

American Journal of Transplantation Pub Date : 2025-04-01 DOI: 10.1016/j.ajt.2024.11.009

Nynke Wijbenga , Bas J. Mathot , Roel van Pel , Leonard Seghers , Catharina C. Moor , Joachim G.J.V. Aerts , Daniel Bos , Olivier C. Manintveld , Merel E. Hellemons

{"title":"The ability of an electronic nose to distinguish between complications in lung transplant recipients","authors":"Nynke Wijbenga , Bas J. Mathot , Roel van Pel , Leonard Seghers , Catharina C. Moor , Joachim G.J.V. Aerts , Daniel Bos , Olivier C. Manintveld , Merel E. Hellemons","doi":"10.1016/j.ajt.2024.11.009","DOIUrl":"10.1016/j.ajt.2024.11.009","url":null,"abstract":"<div><div>Complications like acute cellular rejection (ACR) and infection are known risk factors for the development of chronic lung allograft dysfunction, impacting long-term patient and graft survival after lung transplantation (LTx). Differentiating between complications remains challenging and time-sensitive, highlighting the need for accurate and rapid diagnostic modalities. We assessed the ability of exhaled breath analysis using an electronic nose (eNose) to distinguish between ACR, infection, and mechanical complications in LTx recipients (LTR) presenting with suspected complications. LTR with suspected complications and subsequently proven diagnosis underwent exhaled breath analysis using an eNose. Supervised machine learning was used to assess the eNose’s ability to discriminate between complications. Next, we determined the added value of the eNose measurement on top of standard clinical parameters. In 90 LTR, 161 measurements were performed during suspected complications, with 84 proven diagnoses. The eNose could distinguish between ACR, infection, and mechanical complications with 74% accuracy, and ACR and infection with 82% accuracy. Combining eNose measurements with standard clinical parameters improved diagnostic accuracy to 88% (<em>P</em> =.0139), with 94% sensitivity and 80% specificity. Exhaled breath analysis using eNose technology is a promising, noninvasive, diagnostic modality for distinguishing LTx complications, enabling timely diagnosis and interventions.</div></div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 4","pages":"Pages 804-813"},"PeriodicalIF":8.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142685537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tenofovir-associated Fanconi syndrome in liver transplant recipients with hepatitis B: A retrospective case series 乙肝肝移植受者的替诺福韦相关范可尼综合征：回顾性病例系列

IF 8.9 2区医学

American Journal of Transplantation Pub Date : 2025-04-01 DOI: 10.1016/j.ajt.2024.12.015

Erica Loon , Nicholas Lim , Giovanni A. Roldan , John Lake

引用次数: 0

Domino partial heart transplantation 多米诺部分心脏移植。

IF 8.9 2区医学

American Journal of Transplantation Pub Date : 2025-04-01 DOI: 10.1016/j.ajt.2024.12.013

Benjamin Alexander, Eli Contorno, Herra Javed, Nicholas Callais, Taufiek K. Rajab

引用次数: 0

The Rochester Protocol for living donor liver transplantation of unresectable colorectal liver metastasis: A 5-year report on selection, approval, and outcomes 罗切斯特未切除大肠癌肝转移活体肝移植协议》：关于选择、批准和结果的五年报告。

IF 8.9 2区医学

American Journal of Transplantation Pub Date : 2025-04-01 DOI: 10.1016/j.ajt.2024.09.027

Matthew M. Byrne , Mariana Chávez-Villa , Luis I. Ruffolo , Anthony Loria , Yutaka Endo , Amber Niewiemski , Cristina Jimenez-Soto , Jennifer I. Melaragno , Gopal A. Ramaraju , Priya D. Farooq , Richard F. Dunne , Karen Pineda-Solis , Amit Nair , Mark Orloff , Koji Tomiyama , Roberto Hernandez-Alejandro

{"title":"The Rochester Protocol for living donor liver transplantation of unresectable colorectal liver metastasis: A 5-year report on selection, approval, and outcomes","authors":"Matthew M. Byrne , Mariana Chávez-Villa , Luis I. Ruffolo , Anthony Loria , Yutaka Endo , Amber Niewiemski , Cristina Jimenez-Soto , Jennifer I. Melaragno , Gopal A. Ramaraju , Priya D. Farooq , Richard F. Dunne , Karen Pineda-Solis , Amit Nair , Mark Orloff , Koji Tomiyama , Roberto Hernandez-Alejandro","doi":"10.1016/j.ajt.2024.09.027","DOIUrl":"10.1016/j.ajt.2024.09.027","url":null,"abstract":"<div><div>Living donor liver transplantation (LDLT) is a treatment option for select patients with unresectable colorectal liver metastasis. We describe our center’s experience of patient selection, insurance approval, and outcomes after LDLT after first referral in March 2019. Of the 206 evaluated patients, 23 underwent LDLT. We found that patients who were referred earlier in their oncologic course were more likely to be eligible for transplantation. After completion of the Rochester Protocol for LDLT eligibility, recipients had a median delay of care of 10 days (IQR, 0-36 days) related to insurance appeal, with 6 patients (30%) having a delay longer than 30 days. LDLT recipients had an overall survival proportion of 100% and 91% at 1 and 3 years and a recurrence-free survival proportion of 100% and 40% at 1 and 3 years, respectively. All donors underwent right hepatectomy, of which only 1 donor had a Clavien-Dindo IIIa complication and readmission. There was no donor mortality. We assert that multidisciplinary care and strict patient selection through the Rochester Protocol were paramount to our center’s success. In the appropriately selected patient, LDLT for unresectable colorectal liver metastasis may be justified, and patients should be referred to transplant oncology centers for evaluation.</div></div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 4","pages":"Pages 780-792"},"PeriodicalIF":8.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142329254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Durable mixed chimerism may permit subsequent immunosuppression-free intestinal transplantation—A proof-of-principle study 持久的混合嵌合体可允许无免疫抑制的后续肠道移植--一项原则性研究。

IF 8.9 2区医学

American Journal of Transplantation Pub Date : 2025-04-01 DOI: 10.1016/j.ajt.2024.10.014

Satyajit Patwardhan , Muhammed E. Gunes , Elin Manell , Julie Hong , Philip Jordache , Ishit Chauhan , Ahmed Almesallmy , Harko Mulder , Dilrukshi Ekanayake-Alper , Dominik Hajosi , Huaibin M. Ko , Kumaran Shanmugarajah , Curtis L. Cetrulo , Greg Nowak , David H. Sachs , Megan Sykes , Joshua Weiner

{"title":"Durable mixed chimerism may permit subsequent immunosuppression-free intestinal transplantation—A proof-of-principle study","authors":"Satyajit Patwardhan , Muhammed E. Gunes , Elin Manell , Julie Hong , Philip Jordache , Ishit Chauhan , Ahmed Almesallmy , Harko Mulder , Dilrukshi Ekanayake-Alper , Dominik Hajosi , Huaibin M. Ko , Kumaran Shanmugarajah , Curtis L. Cetrulo , Greg Nowak , David H. Sachs , Megan Sykes , Joshua Weiner","doi":"10.1016/j.ajt.2024.10.014","DOIUrl":"10.1016/j.ajt.2024.10.014","url":null,"abstract":"<div><div>Intestinal transplantation (ITx) is the definitive treatment for intestinal failure but has the highest rejection rate among solid organ transplants, requiring high doses of immunosuppressive medication, which is associated with high rates of infection, graft-versus-host disease, and malignancy. Transplant tolerance would overcome the need for long-term immunosuppression (ISP). Using nonmyeloablative conditioning, our laboratory has developed a novel swine model of hematopoietic stem cell transplantation (HSCT) that produces durable mixed chimerism (MC) and immune tolerance without toxicity. We investigated whether durable MC would promote tolerance of subsequently transplanted donor-matched intestinal allografts without ISP. Using miniature swine with a defined major histocompatibility complex (MHC), we performed HSCT across an MHC-class-I haplotype mismatch. Immunosuppressive therapy was stopped by day 45. MC was evaluated using flow cytometry, and mixed lymphocyte reaction assays were used to evaluate cellular responses. Subsequently, orthotopic ITx was performed without ISP using a donor that was MHC-matched to the HSCT donor. The recipients were observed for 4 weeks and euthanized for tissue collection and mechanistic assays. After HSCT, the recipients developed durable multilineage MC and apparent deletional tolerance. After ITx, recipients showed no clinical or histologic signs of rejection, and chimerism was unchanged. These results demonstrate the potential value of generating durable MC to achieve transplant tolerance.</div></div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 4","pages":"Pages 825-835"},"PeriodicalIF":8.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142489408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical outcomes of pediatric kidney replacement therapy after childhood cancer—An ESPN/ERA Registry study 儿童癌症后小儿肾脏替代治疗的临床结果 - ESPN/ERA 登记研究。

IF 8.9 2区医学

American Journal of Transplantation Pub Date : 2025-04-01 DOI: 10.1016/j.ajt.2024.11.002

Henna Kaijansinkko , Marjolein Bonthuis , Kirsi Jahnukainen , Jerome Harambat , Enrico Vidal , Sevcan A. Bakkaloglu , Carol Inward , Manish D. Sinha , Rosa M. Roperto , Claudia E. Kuehni , Erika Biró , Theresa Kwon , Conceição Mota , Brigitte Adams , Maria Szczepańska , Beata Bieniaś , Britta Höcker , Svitlana Fomina , Ann Christin Gjerstad , Karel Vondrak , Timo Jahnukainen

{"title":"Clinical outcomes of pediatric kidney replacement therapy after childhood cancer—An ESPN/ERA Registry study","authors":"Henna Kaijansinkko , Marjolein Bonthuis , Kirsi Jahnukainen , Jerome Harambat , Enrico Vidal , Sevcan A. Bakkaloglu , Carol Inward , Manish D. Sinha , Rosa M. Roperto , Claudia E. Kuehni , Erika Biró , Theresa Kwon , Conceição Mota , Brigitte Adams , Maria Szczepańska , Beata Bieniaś , Britta Höcker , Svitlana Fomina , Ann Christin Gjerstad , Karel Vondrak , Timo Jahnukainen","doi":"10.1016/j.ajt.2024.11.002","DOIUrl":"10.1016/j.ajt.2024.11.002","url":null,"abstract":"<div><div>Cancer and its treatment may lead to kidney injury and the need for kidney replacement therapy (KRT). We identified 287 pediatric KRT patients with a history of malignancy from the European Society for Paediatric Nephrology/European Renal Association Registry. Of these, 197 had cancer as a primary cause of KRT (group 1) and 90 had a malignancy diagnosis before KRT (group 2). Two matched controls without malignancy were randomly selected for each patient. Data were complemented with a questionnaire. Median time to kidney transplantation (KT) from KRT initiation was 2.4 (IQR: 1.5-4.7), 1.5 (IQR: 0.4-3.3), 3.6 (IQR: 1.3 to Q3 not reached), and 1.1 (IQR: 0.3-3.6) years for group 1, their controls, group 2, and their controls, respectively. Overall 10-year mortality for those on KRT was higher among cancer patients vs controls in group 1: 16% vs 9% (adjusted hazard ratio 2.02, 95% CI: 1.21-3.37) and in group 2: 23% vs 14% (adjusted hazard ratio 2.32, 95% CI: 1.11-4.85). In contrast, 10-year patient survival after the first KT was comparable to controls (93% vs 96%; 100% vs 94%, in groups 1 and 2, respectively). In summary, childhood cancer survivors’ KT was delayed, and their overall mortality when on KRT was increased, but once transplanted, their long-term outcome was similar to other KT recipients.</div></div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 4","pages":"Pages 767-779"},"PeriodicalIF":8.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A novel intravascular bioartificial pancreas device shows safety and islet functionality over 30 days in nondiabetic swine 一种新型血管内生物人工胰腺装置在非糖尿病猪身上显示出三十天的安全性和胰岛功能。

IF 8.9 2区医学

American Journal of Transplantation Pub Date : 2025-04-01 DOI: 10.1016/j.ajt.2024.11.012

Sara Photiadis , Quynh Mai , Gabriel Montanez , Christopher Nguyen , Thomas Kramer , Douglas Photiadis , Charles Sylvia , Taylor Spangler , Khanh Hoa Nguyen

{"title":"A novel intravascular bioartificial pancreas device shows safety and islet functionality over 30 days in nondiabetic swine","authors":"Sara Photiadis , Quynh Mai , Gabriel Montanez , Christopher Nguyen , Thomas Kramer , Douglas Photiadis , Charles Sylvia , Taylor Spangler , Khanh Hoa Nguyen","doi":"10.1016/j.ajt.2024.11.012","DOIUrl":"10.1016/j.ajt.2024.11.012","url":null,"abstract":"<div><div>In this study using a discordant, xenogeneic, transplant model we demonstrate the functionality and safety of the first stent-based bioartificial pancreas (BAP) device implanted endovascularly into an artery, harnessing the high oxygen content in blood to support islet viability. The device is a self-expanding nitinol stent that is coated with a bilayer of polytetrafluoroethylene that forms channels to hold islets embedded in a hydrogel. We completed a 1-month study in the nondiabetic swine model (N = 3) to test the safety of the device and to assess islet functionality after device recovery. The luminal diameter of the devices from 3 animals on day 0 and day 30 was 10.01 ± 0.408 mm and 10.05 ± 0.25 mm, respectively. The stimulation index of the control and endovascular BAP devices explanted at day 30 were 3.35 ± 0.97 and 4.83 ±1.20, respectively, and the islets stained positively for insulin and glucagon after 30 days in vivo. This pilot study shows that BAP implantation into a peripheral artery is safe and supports islet functionality over 30 days, providing the groundwork for future work assessing the in vivo function of the device in diabetic swine.</div></div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 4","pages":"Pages 734-743"},"PeriodicalIF":8.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142666235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0